Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.56 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12985251 | 0.85 | MAPT (0.56) | SMN1; SMN2ALDH1A1MAPTTP53LMNA | |
| SCHEMBL4113212 | 0.82 | CYP4F2 (0.76) | CYP4F2CYP4A11SMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL11041084 | 0.81 | POLB (0.44) | SMN1; SMN2ALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL14418359 | 0.80 | SLC7A5 (0.50) | CYP4F2CYP4A11SMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL9053071 | 0.80 | EPHX2 (0.50) | CYP4F2CYP4A11NPC1RAB9AL3MBTL1 | |
| SCHEMBL27864655 | 0.79 | CYP4F2 (0.61) | CYP4F2CYP4A11SMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL693471 | 0.79 | CA2 (0.52) | SMN1; SMN2ALDH1A1RAB9ATP53LMNA | |
| SCHEMBL2286242 | 0.79 | CYP4F2 (0.61) | CYP4F2CYP4A11SMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL4765888 | 0.79 | CYP4F2 (0.56) | CYP4F2CYP4A11SMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL9825759 | 0.79 | ALDH1A1 (0.41) | SMN1; SMN2ALDH1A1MAPTLMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103936716-B | Tool muscarinic receptor antagonists and the diamide compound of beta 2 adrenoreceptor agonists activity | 施万呼吸有限责任公司 | 2016-09-07 | — | — | CN | disclosed |
| EP-2119476-B1 | Amide derivatives as positive allosteric modulators and methods of use thereof | ABBVIE INC (US) | 2014-03-19 | — | — | EP | disclosed |
| US-7994223-B2 | Amide derivatives as positive allosteric modulators and methods of use thereof | ABBOTT LABORATORIES (US) | 2011-08-09 | — | — | US | disclosed |
| CN-102056898-A | Amide derivatives as positive allosteric modulators and methods of use thereof | ABBOTT LAB | 2011-05-11 | — | — | CN | disclosed |
| US-20100286109-A1 | AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-11-11 | — | — | US | disclosed |
| US-7786171-B2 | Amide derivatives as positive allosteric modulators and methods of use thereof | ABBOTT LABORATORIES (US) | 2010-08-31 | — | — | US | disclosed |
| WO-2009145996-A2 | AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-12-03 | — | — | WO | disclosed |
| EP-2119476-A2 | Amide derivatives as positive allosteric modulators and methods of use thereof | ABBOTT LABORATORIES (US) | 2009-11-18 | — | — | EP | disclosed |
| US-20090253670-A1 | AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286109-A1 | AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | CHRNA4, CHRNA2, CHRNA3 | CYP4F2 4324/4885CYP4A11 4126/4885SMN1; SMN2 1018/4885 |
| US-20090253670-A1 | AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | CHRNA4, CHRNA2, CHRNA3 | CYP4F2 4324/4885CYP4A11 4126/4885SMN1; SMN2 1018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.